10-K: Nuo Therapeutics Announces 2024 Results and New Distribution Agreement with Smith+Nephew

Nuo Therapeutics reports increased revenues for 2024 and a new distribution agreement with Smith+Nephew for its Aurix product.

Summary

• Nuo Therapeutics, a regenerative therapies company, reported increased product revenues for the year ended December 31, 2024, reaching approximately $1.365 million compared to $609,000 in 2023.
• The company's net loss for 2024 was approximately $2.3 million, an improvement from the $3.2 million loss in 2023.
• Nuo Therapeutics entered into a distribution agreement with Smith+Nephew on March 31, 2025, granting Smith+Nephew exclusive rights to distribute a private label version of the Aurix product in the United States.
• The agreement includes minimum annual purchase commitments for Smith+Nephew averaging approximately $500,000 per year to maintain exclusive distribution rights.
• Smith+Nephew will pay Nuo Therapeutics up to $2.25 million for distribution rights and reimbursement establishment.
• The company's management expresses substantial doubt about its ability to continue as a going concern without securing additional funding.
• Nuo Therapeutics had 9 full-time employees as of December 31, 2024.
• The company is subject to extensive governmental regulation, including FDA requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue increased and losses decreased, the company's going concern status and need for additional funding temper the positive aspects. The Smith+Nephew deal is a potential positive, but its success is not guaranteed.

Positives

• Product revenues increased significantly in 2024, indicating growing market adoption of the Aurix product.
• The net loss decreased in 2024 compared to 2023, suggesting improved financial performance.
• The distribution agreement with Smith+Nephew provides a potential revenue stream and market access.
• CMS reimbursement rates for the Aurix System have been established, improving the economic viability of the product.
• The company has established contractual relationships with more than 200 third-party entity and individual representatives including a multi-state agreement with Pacific Medical, Inc.

Negatives

• The company has a history of losses and is not currently profitable.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's revenue base is limited to a single product.
• The company has a limited operating history and limited operating experience.
• The company relies on a single supplier for a key reagent used in the Aurix product.
• The company's management concluded there was a material weakness in our internal control over financial reporting as of the period covered by this Annual Report.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• The success of the Aurix product depends on acceptance by the medical community and patients.
• The company faces competition in the chronic wound care market.
• The company is subject to governmental regulation, including FDA requirements.
• The company's intellectual property assets are critical to its success and may be subject to misappropriation or infringement.
• The company may be affected by malpractice or product liability claims.
• There can be no assurance that Smith+Nephew will be able to establish a market for its Private Label product.
• Fulfilling Purchase Orders under the Distribution Agreement Will Place Demands on our Management and Financial Resources.
• The Existence of a Private Label Alternative to our Aurix Product May Limit the Potential Customers and Sales for our Aurix Product.
• If Smith+Nephew Determines that Marketing and Sales of its Private Label Product Do Not Meet Its Expectations or Priorities, then Smith+Nephew May Terminate the Distribution Agreement.

Future Outlook

The company expects revenues to continue growing in the future but needs to raise substantial additional funds to continue its business.

Industry Context

The advanced wound care market is estimated to be an approximately $10.8 billion global market in 2021, with the North American market estimated at approximately $4.15 billion in 2020.

Comparison to Industry Standards

• Leading companies in the advanced wound care market include Smith+Nephew, 3M, MoInlycke, and ConvaTec.
• Leading competitors in the wound care market that offer other biologic products such as tissue-based products include companies such as MiMedx, Organogenesis, Integra Life Sciences, as well as a significant number of smaller companies.

Related Party Transactions

• In August and December 2023, certain related parties including a principal shareholder, a member of the Board of Directors, and a member of senior management invested an aggregate of $760,000 in the two 2023 private placement transactions.
• In May and September 2024, certain related parties including a principal shareholder, a member of the Board of Directors, and a member of senior management invested an aggregate of $281,250 in the two 2024 private placement transactions.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances.
• Employees' job security is uncertain due to the company's going concern status.
• Customers may benefit from the Smith+Nephew distribution agreement, potentially leading to wider availability of the Aurix product.
• Suppliers may be affected by the company's financial situation and potential need to reduce costs.

Next Steps

• The company will continue engaging and establishing relationships with providers treating chronic non-healing wounds.
• The company will continue to implement measures designed to improve its internal control over financial reporting to remediate the identified material weaknesses.

Key Dates

Keywords

Aurix, Nuo Therapeutics, Smith+Nephew, Distribution Agreement, Wound Care, Regenerative Therapies, Financial Results, Reimbursement, Private Label, Medicare, Revenue, Net Loss